Skip to content

Exploratory study of IK-01 for knee osteoarthritis

An open-label, multi-center exploratory study to investigate the efficacy and safety of autologous chondrocyte processed product (IK-01) for knee osteoarthritis

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2053220084
Enrollment
10
Registered
2022-09-02
Start date
2022-09-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis of the knee

Interventions

IK-01 is transplanted or IK-01 is transplanted simultaneously with high tibial osteotomy in patients with knee osteoarthritis

Sponsors

Otsuka Koji
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Patients who have provided written informed consent using an IRB-approved explanation/consent form - Patients aged 20 to less than 75 years at the time of informed consent - Patients diagnosed with knee osteoarthritis according to the ACR classification criteria for knee osteoarthritis (clinical findings and X-ray imaging findings) during the screening period - Patients diagnosed with knee osteoarthritis of Kellgren-Lawrence grade 2 or 3 on standing frontal X-ray findings during the screening period

Exclusion criteria

Exclusion criteria: - Patients have multiple arthropathies in the lower extremities - Patients with a history of or need to undergo surgery such as knee meniscectomy or suturing at the time of informed consent. However, if there is a history of meniscal resection or suturing, patients who have passed a certain period (8 weeks or more) after surgery can be enrolled - Patients with a history of or need surgery such as ligament reconstruction for ligament damage of the evaluation target knee at the time of informed consent. However, patients who have passed a certain period (8 weeks or more) after surgery can be enrolled - Patients who are judged to be inappropriate by the principal investigator or sub investigator

Design outcomes

Primary

MeasureTime frame
Change from baseline in the WOMAC total score at 52 weeks post-transplantation

Contacts

Public ContactRegenerative medicine Products Development

Hirosaki Lifescience Innovation, Inc.

info@hirosaki-li.co.jp+81-3-6457-9861

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026